Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: Focus on dosing regimen, dosage form, and formulation

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 4, 2005, Pages 322-329

  Chen, Mei Ling ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALAT CC; ALPRAZOLAM; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMAZEPAM; BUSPIRONE; CALAN SR; CALCIUM CHANNEL BLOCKING AGENT; COVERA SR; CYCLOSPORIN; DILTIAZEM; EBASTINE; FELODIPINE; GLYCERYL TRINITRATE; METHADONE; MEVINOLIN; MIDAZOLAM; NEFAZODONE; NIFEDIPINE; NIMODIPINE; OMEPRAZOLE; PREDNISOLONE; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TIRILAZAD; TRAZODONE; TRIAZOLAM; VERAPAMIL;

BIOEQUIVALENCE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; ENTERIC COATED TABLET; HUMAN; MULTIPLE DRUG DOSE; NOTE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE DRUG DOSE;

CHEMISTRY, PHARMACEUTICAL; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYTOCHROME P-450 ENZYME SYSTEM; DOSAGE FORMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY; SEX FACTORS;

EID: 25844507083     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.06.012     Document Type: Note

References (77)

1. P.L. Bonate Gender-related differences in xenobiotic metabolism J Clin Pharmacol 31 1991 684 690
2. C.V. Fletcher, E.P. Acosta, J.M. Strykowski Gender differences in human pharmacokinetics and pharmacodynamics J Adolesc Health 15 1994 619 629
3. R.Z. Harris, L.Z. Benet, J.B. Schwartz Gender effects in pharmacokinetics and pharmacodynamics Drugs 50 1995 222 239
4. C.H. Gleiter, U. Gundert-Remy Gender differences in pharmacokinetics Eur J Drug Metab Pharmacokinet 21 1996 123 128
5. I. Beierle, B. Meibohm, H. Derendorf Gender effects in pharmacokinetics and pharmacodynamics Int J Clin Pharmacol Ther 11 1999 529 547
6. B. Meibohm, I. Beierle, H. Derendorf How important are gender effects in pharmacokinetics? Clin Pharmacokinet 41 2002 329 342
7. J.B. Schwartz The influence of sex on pharmacokinetics Clin Pharmacokinet 42 2003 107 121
8. R.R. Bies, K.L. Bigos, B.G. Pollock Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants J Gend Specif Med 6 2003 12 20
9. M.D. Donovan Sex and racial differences in pharmacological response effect of route of administration and drug delivery system on pharmacokinetics J Womens Health (Larchmt) 14 2005 30 37
10. C.L. Cummins, C.Y. Wu, L.Z. Benet Sex-related differences in the clearance of cytochrome P-450 3A4 substrates may be caused by P-glycoprotein Clin Pharmacol Ther 72 2002 474 489
11. A. Wald, D.H. van Thiel, L. Hoechstetter, J.S. Gavaler, K.M. Egler, R. Verm Gastrointestinal transit the effect of the menstrual cycle Gastroenterology 80 1981 1497 1500
12. F.L. Datz, P.E. Christian, J. Moore Gender-related difference in gastric emptying J Nucl Med 28 1987 1204 1207
13. W.R. Hutson, R.L. Roehrkasse, A. Wald Influence of gender and menopause on gastric emptying and motility Gastroenterology 96 1989 11 17
14. R. Meier, C. Beglinger, J.P. Dederding, B. Meyer-Wyss, M. Fumagalli, A. Rowedder Influence of age, gender, hormonal status and smoking habits on colonic transit time Neurogastroenterol Motil 7 1995 235 238
15. L.P. Degen, S.F. Phillips Variability of gastrointestinal transit in healthy women and men Gut 39 1996 299 305
16. J. Graff, K. Brinch, J.L. Madsen Gastrointestinal mean transit times in young and middle-aged healthy subjects Clin Physiol 21 2001 253 259
17. M.M. Cotreau, L.L. von Moltke, D.J. Greenblatt The influence of age and sex on the clearance of cytochrome P450 3A substrates Clin Pharmacokinet 44 2005 33 60
18. D.J. Greenblatt, M. Divoll, D.R. Abernethy, L.J. Moschitto, R.B. Smith, R.I. Shader Alprazolam kinetics in the elderly Arch Gen Psychiatry 40 1983 287 290
19. C. Kirkwood, A. Moore, P. Hayes, C.L. DeVane, A. Pelonero Influence of menstrual cycle and gender on alprazolam pharmacokinetics Clin Pharmacol Ther 50 1991 404 409
20. F. Kristjansson Disposition of alprazolam in human volunteers. Differences between genders Acta Pharm Nord 3 1991 249 250
21. D.M. Gibson, N.J. Bron, A. Richens, N.J. Hounslow, A.J. Sedman, L.R. Whitfield Effect of age and gender on pharmacokinetics of atorvastatin in humans J Clin Pharmacol 36 1996 242 246
22. H.R. Ochs, D.J. Greenblatt, H. Friedman, E.S. Burstein, A. Locniskar, J.S. Harmatz Bromazepam pharmacokinetics influence of age, gender, oral contraceptives, cimetidine, and propranolol Clin Pharmacol Ther 41 1987 562 570
23. R.E. Grammans, M.L. Westrick, J.P. Shea, R.F. Mayol, J.A. LaBudde Pharmacokinetics of buspirone in elderly subjects J Clin Pharmacol 29 1989 72 78
24. A. Sakr, M. Andheria A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product J Clin Pharmacol 41 2001 886 894
25. T.J. Schroeder, M.J. Cho, G.M. Pollack, R. Floc'h, H.B. Moran, R. Levy Comparison of two cyclosporine formulations in healthy volunteers bioequivalence of the new Sang-35 formulation and Neoral J Clin Pharmacol 38 1998 807 814
26. D.I. Min, Miyoung Lee, Y.M. Ku, M. Flanigan Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers Clin Pharmacol Ther 68 2000 478 486
27. J.S. Bleck, C. Thiesemann, V. Kliem, U. Christians, H. Hecker, H. Repp Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients Br J Clin Pharmacol 41 1996 551 556
28. D. Saenz-Campos, M.C. Bayes, S. Martin, M.J. Barbanoj, F. Jane Gender related pharmacokinetics of diltiazem in healthy subjects Int J Clin Pharmacol Ther 33 1995 397 400
29. P.K.F. Yeung, C. Prescott, C. Haddad, T.J. Montague, C. McGregor, M.A. Quilliam Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose Eur J Drug Metab Pharmacokinet 18 1993 199 206
30. S. Rohatagi, M. Gillen, M. Aubeneau, C. Jan, B. Pandit, B.K. Jensen Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects Int J Clin Pharmacol Ther 39 2001 126 134
31. E. Blychert Felodipine pharmacokinetics and plasma concentration vs effect relationship Blood Press Suppl 2 1992 1 30
32. H. Cheng, J.D. Rogers, A.E. Sweany, M.R. Dobrinska, E.A. Stein, A.C. Tate Influence of age and gender on the plasma profiles of 3-hydroxy-3- methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin Pharm Res 9 1992 1629 1633
33. J.W. De Vos, P.J. Geerlings, W. van den Brink, J.G.R. Ufkes, H. van Wilgenburg Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts Eur J Clin Pharmacol 48 1995 361 366
34. J.C. Gorski, D.R. Jones, B.D. Haehner-Daniels, M.A. Hamman, E.M. O'Mara, S.D. Hall The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin Clin Pharmacol Ther 64 1998 133 143
35. S.M. Tsunoda, R.L. Velez, L.L. von Moltke, D.J. Greenblatt Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe effect of ketoconazole Clin Pharmacol Ther 66 1999 461 471
36. K.E. Thummel, D. O'Shea, M.F. Paine, D.D. Shen, K.L. Kunze, J.D. Perkins Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism Clin Pharmacol Ther 59 1996 491 502
37. J.C. Gorski, S. Vannaprasaht, M.A. Hamman, W.T. Ambrosius, M.A. Bruce, B. Haehner-Daniels The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity Clin Pharmacol Ther 74 2003 275 287
38. R.H. Barhaiya, A.B. Buch, D.S. Greene A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses J Clin Psychopharmacol 16 1996 19 25
39. M.E. Krecic-Shepard, K. Park, C. Barnas, J. Slimko, D.R. Kerwin, J.B. Schwartz Race and sex influence clearance of nifedipine results of a population study Clin Pharmacol Ther 68 2000 130 142
40. J. Lobo, D.B. Jack, M.J. Kendall The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers Eur J Clin Pharmacol 30 1986 57 60
41. W. Muck, H.P. Breuel, J. Kuhlmann The influence of age on the pharmacokinetics of nimodipine Int J Clin Pharmacol Ther 34 1996 293 298
42. M.H. Magee, R.A. Blum, C.D. Lates, W.J. Jusko Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race J Clin Pharmacol 41 2001 1180 1194
43. D.J. Greenblatt, H. Friedman, E.S. Burstein, J.M. Scavone, G.T. Blyden, H.R. Ochs Trazodone kinetics effect of age, gender, and obesity Clin Pharmacol Ther 42 1987 193 200
44. R.B. Smith, M. Divoll, W.R. Gillespie, D.J. Greenblatt Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam J Clin Psychopharmacol 3 1983 172 176
45. D.J. Greenblatt, M. Divoll, D.R. Abernethy, L.J. Moschitto, R.B. Smith, R.I. Shader Reduced clearance of triazolam in old age relation to antipyrine oxidizing capacity Br J Clin Pharmacol 15 1983 303 309
46. D.J. Greenblatt, J.S. Harmatz, T.A. Gouthro, J. Locke, R.I. Shader Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography kinetic-dynamic studies Clin Pharmacol Ther 56 1994 100 111
47. D.J. Greenblatt, J.S. Harmatz, L.L. von Moltke, C.E. Wright, A.L.B. Durol, L.M. Harrel-Joseph Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem evaluation of sex-dependent differences J Pharmacol Exp Ther 293 2000 435 443
48. D.J. Greenblatt, J.S. Harmatz, L. Shapiro, N. Engelhardt, T.A. Gouthro, R.I. Shader Sensitivity to triazolam in the elderly N Engl J Med 324 1991 1891 1898
49. D.J. Greenblatt, J.S. Harmatz, L.L. von Moltke, E. Wright, R.I. Shader Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate Clin Pharmacol Ther 76 2004 467 479
50. M.E. Krecic-Shepard, C.R. Barnas, J. Slimko, M.P. Jones, J.B. Schwartz Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans J Clin Pharmacol 40 2000 219 230
51. M.E. Krecic-Shepard, C.R. Barnas, J. Slimko, J.B. Schwartz Faster clearance of sustained release verapamil in men versus women continuing observations on sex-specific differences after oral administration of verapamil Clin Pharmacol Ther 68 2000 286 292
52. S.K. Gupta, L. Atkinson, T. Tu, J.A. Longstreth Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil Br J Clin Pharmacol 40 1995 325 331
53. K. Dilger, K. Eckhardt, U. Hofmann, K. Kucher, G. Mikus, M. Eichelbaum Chronopharmacology of intravenous and oral modified release verapamil Br J Clin Pharmacol 47 1999 413 419
54. D. Kang, D. Verotta, M.E. Krecic-Shepard, N.B. Modi, S.K. Gupta, J.B. Schwartz Population analyses of sustained-release verapamil in patients effects of sex, race, and smoking Clin Pharmacol Ther 73 2003 31 40
55. A. Oliva Efficacy of tirilazad mesylate in aneurysmal subarachnoid hemorrhage Peripheral and Central Nervous System Drugs Advisory Committee Meeting; Food and Drug Administration 1999 Apr 29; Gaithersburg, Maryland.
56. L.K. Hulst, J.C. Fleishaker, G.R. Peters, J.D. Harry, D.M. Wright, P. Ward Effect of age and gender on tirilazad pharmacokinetics in humans Clin Pharmacol Ther 55 1994 378 384
57. J.C. Fleishaker, L.K. Pearson, G.R. Peters Gender does not affect the degree of induction of tirilazad clearance by phenobarbital Eur J Clin Pharmacol 50 1996 139 145
58. J.C. Fleishaker, L.K. Pearson, P.G. Pearson, L.C. Wienkers, N.K. Hopkins, G.R. Peters Hormonal effects on tirilazad clearance in women assessment of the role of CYP3A J Clin Pharmacol 39 1999 260 267
59. J.C. Fleishaker, J. Fiedler-Kelly, T.H. Grasela Population pharmacokinetics of tirilazad effects of weight, gender, concomitant phenytoin, and subarachnoid hemorrhage Pharm Res 16 1999 55 83
60. P.C. Ho, E.J. Triggs, D.W.A. Bourne The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites Br J Clin Pharmacol 19 1985 675 684
61. J.O. Miners, N. Grgurinovich, A.G. Whitehead, R.A. Robson, D.J. Birkett Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid Br J Clin Pharmacol 22 1986 135 142
62. L. Aarons, K. Hopkins, M. Rowland, S. Brossel, J.F. Thiercelin Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt Pharm Res 6 1989 660 666
63. P. Mojaverian, M.L. Rocci Jr, D.P. Conner, W.B. Abrams, P.H. Vlasses Effect of food on the absorption of enteric-coated aspirin correlation with gastric residence time Clin Pharmacol Ther 41 1987 11 17
64. R. Wolbold, K. Klein, O. Burk, A.K. Nussler, P. Neuhaus, M. Eichelbaum Sex is a major determinant of CYP3A4 expression in human liver Hepatology 38 2003 978 988
65. E.G. Schuetz, K.N. Furuya, J.D. Schuetz Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms J Pharmacol Exp Ther 275 1995 1011 1018
66. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, C.L. Marsh Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J Pharmacol Exp Ther 283 1997 1552 1562
67. I. de Waziers, P.H. Cugnenc, C.S. Yang, J.-P. Leroux, P.H. Beaune Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues J Pharmacol Exp Ther 253 1990 387 394
68. M.F. Paine, S.S. Ludington, M.-L. Chen, P.W. Stewart, S.-M. Huang, P.B. Watkins Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos 33 2005 426 433
69. R.H. Stephens, C.A. O'Neill, A. Warhurst, G.L. Carlson, M. Rowland, G. Warhurst Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia J Pharmacol Exp Ther 296 2001 584 591
70. S. Mouly, M.F. Paine P-glycoprotein increases from proximal to distal regions of human small intestine Pharm Res 20 2003 1595 1599
71. C. Zimmermann, H. Gutmann, P. Hruz, J.P. Gutzwiller, C. Beglinger, J. Drewe Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract Drug Metab Dispos 33 2005 219 224
72. T. Zimmermann, H. Laufen, R. Yeates, F. Scharpf, K.D. Riedel, T. Schumacher The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times J Clin Pharmacol 39 1999 1021 1031
73. Physicians' desk reference (PDR) 57th ed. 2003 Thomson PDR Montvale (NJ)
74. Physicians' desk reference (PDR) 59th ed. 2005 Thomson PDR Montvale (NJ)
75. T. Bussemer, I. Otto, R. Bodmeier ulsatile drug-delivery systems Crit Rev Ther Drug Carrier Syst 18 2001 433 458
76. M.-L. Chen, S.-C. Lee, M.-J. Ng, D.J. Schuirmann, L.J. Lesko, R.L. Williams Pharmacokinetic analysis of bioequivalence trials implications for sex-related issues in clinical pharmacology and biopharmaceutics Clin Pharmacol Ther 68 2000 510 521
77. R.L. Williams, M.-L. Chen, W.W. Hauck Equivalence approaches Clin Pharmacol Ther 72 2002 229 237